Daxx过表达对氧化应激诱导的肝肿瘤细胞凋亡的影响

死亡结构域相关蛋白Daxx可以敏化多种肿瘤细胞的凋亡过程,但对于肝肿瘤细胞株HepG2的影响未见报道．为了研究Daxx增加肝HepG2细胞对药物敏感性的影响及机制,为开发药物新的药理作用提供理论依据,分别转染pEGFP-C1和pEGFP-C1-Daxx这两个载体到HepG2细胞．实验分组如下：（1）正常对照组（未转染细胞组）;（2）pEGFP-C1空载体转染组（HepG2/GFP细胞）;（3）pEGFP-C1-Daxx表达载体转染组（nepG2/GFP-Daxx细胞）．筛选稳定细胞株,用逆转录聚合酶链反应检测mRNA的表达;用过氧化氢孵育24h诱导细胞凋亡,采用MTT法和流式细胞术检测细胞凋亡率,Western blot检测蛋白质的表达．经G418筛选稳定的细胞运用RT-PCR技术分析其mRNA,结果显示,转染绿色荧光蛋白Daxx表达载体的细胞Daxx的mRNA明显上调：用荧光显微镜观察到Daxx蛋白主要定位于细胞核．用过氧化氢诱导HepG2细胞凋亡,观察到过氧化氢呈浓度依赖性地抑制HepG2细胞活性．正常对照细胞、HepG2／GFP、HepG2／GFP-Daxx 3组细胞的IC50值分别是0．72、0．76、0．49mmol／L．并且运用流式细胞仪检测到HepG2／GFP-Daxx组细胞凋亡率明显高于转染空载体质粒组与未转染组（（42．9±8．42）vs（27．3±6．38）or（28．5±4．71））．提示HepG2/GFP-Daxx细胞对过氧化氢的反应性较未转染细胞和HepG2/GFP敏感．还运用Western-blot检测到活化的caspase3在Daxx转染组细胞表达最强,达到（204．66±19．68）％,而未转染和HepG2/GFP组细胞分别是（100±3．1）％、（107．39±20．1）％,进一步说明了Daxx可以增加HepG2细胞对于过氧化氢的敏感性．同时,观察到过氧化氢处理24h后,Daxx转染组细胞磷酸化的JNK表达明显高于空载体转染组和未转染细胞组．上述结果表明：a．Daxx可以增加肝HepG2细胞对过氧化氢诱导的细胞凋亡敏感性;b．Daxx蛋白敏化过氧化氢诱导的HepG2细胞凋亡可能与协同增加JNK活性有关．     

结核分枝杆菌ESX分泌系统研究进展

在结核分枝杆菌中存在能够使某些蛋白通过其高度疏水和通透性极差的细胞壁的分泌系统,其中ESX-1分泌系统负责ESAT-6（early secreted antigenic target of 6 kD）和CFP-10（culture filtrate protein of 10kD）的分泌．这两种蛋白能够形成1：1的二聚体结构,并且是结核分枝杆菌重要的毒力因子．近年来陆续发现其他一些蛋白也由ESX-1分泌系统所分泌．在结核分枝杆菌中还存在其他4种类似ESX-1的分泌系统ESX-2～ESX-5．ESX分泌系统也在其他革兰氏阳性菌和放线菌中被发现,有学者按照公认的术语称其为Ⅶ型分泌系统．本文综述了结核分枝杆菌ESX分泌系统的组成和分子机制,以及分泌蛋白与宿主的相互作用等方面的研究进展．     

靶向survivin的siRNA联合5-Fu转染抑制肝细胞株HepG2增殖的研究

目的：研究靶向survivin的（小分子干扰RNA）siRNA和（氟尿嘧啶）5-FU联用对肝癌细胞HepG2的增殖抑制及凋亡的影响。方法：将HepG2细胞分为空白对照组、阴性对照组、5-FU处理组、siRNA转染组、5-FU＋siRNA转染组。转染采用脂质体法。RT-PCR法检测HepG2细胞survivinmRNA转录水平;MTT法检测靶向survivin的siRNA和5．FU对HepG2细胞增殖的抑制作用;流式细胞术检测HepG2细胞凋亡情况。结果：空白对照组、阴性对照组、5-FU处理组survivinmRNA表达无明显变化（P〉0．05）,siRNA转染组、5-FU＋siRNA转染组survivinmRNA表达明显下降（F=280．326,q=4．72-7．34,P〈0．05）。5-FU＋siRNA转染组增殖抑制率为51．58％±1-35％,与其它各组相比抑制率明显增高（F=280．326,q=5．27-9．84,P〈0．05）。5-Fu＋siRNA组与其它各组相比细胞凋亡率明显增高（F=13568．68,q=110．47-327．16,P〈0．01）。结论：将靶向survivin的siRNA和5一Fu联合应用可以显著抑制肝癌细胞survivin基因表达,并协同抑制HepG2细胞增殖,共同发挥诱导细胞凋亡作用。     

阴道白色念珠菌致病株与携带株两相性与毒力关系研究

目的探讨阴道白色念珠菌致病株和携带株菌丝相和酵母相分泌型酸性蛋白酶和细胞外磷脂酶活性以及与其毒力的关系。方法分别采用牛奶平板和卵黄培养基法检测白色念珠菌致病株和携带株200株分泌型酸性蛋白酶和细胞外磷脂酶的活力,分别将致病产酶株的菌丝相和孢子相菌悬液（5×10^6CFU／ral）注射小鼠尾静脉,1个月内观察小鼠死亡率及平均存活时间,以平均存活时间评价菌株毒力。结果白色念珠菌致病株和携带株分泌型酸性蛋白酶检出率分别为83．3％和35．7％（P〈0．01）;细胞外磷脂酶阳性率分别为87．5％和39．3％（P〈0．01）。动物实验结果表明,白色念珠菌致病株菌丝相分泌型酸性蛋白酶和细胞外磷脂酶的活力均显著高于孢子相（P〈0．01,P〈0．005）;注射菌丝相白色念珠菌的小鼠死亡率高于注射孢子相的小鼠（P〈0．01）,且平均存活期短于注射孢子相的小鼠（P〈0．01）。结论分泌型酸性蛋白酶和细胞外磷脂酶是白色念珠菌重要毒力因子,致病株毒力高于携带株,菌丝相毒力高于酵母相。     

HA纳米载体介导转hGM-CSF基因的HepG2疫苗诱导的抗瘤效应研究

目的：观察HA纳米颗粒载体介导转染hGM-CSF基因的HepG2细胞疫苗体外抗肿瘤效应,为hGM-CSF基因修饰的HepG2细胞疫苗的临床应用提供依据。方法：HA纳米颗粒载体介导hGM-CSF基因转染HepG2细胞制备转GMCSF基因的HepG2细胞疫苗。密度梯度离心法分离人PBMC,体外诱导人PBMC。WST-1法测定PBMC的增殖活性及对HepG2细胞的杀伤效应,流式细胞术分析CD4＋和CD8＋的阳性表达率,ELISA法测定INF-γ的分泌。结果：WST-1结果显示,转基因HepG2组疫苗能诱导PBMC增殖,其增殖率优于野生型疫苗（p〈0.05）;其诱导的PBMC对HepG2的杀伤率高于各野生型疫苗组和各空白对照组（p〈0.05）。FCM结果显示,转基因HepG2疫苗组PBMC中CD4＋和CD8＋阳性表达率均高于各野生型疫苗组和各空白对照组（p〈0.05）。ELISA结果显示,转基因组PBMC培养上清中IFN-γ含量为1989.76±254.21pg/ml,高于各野生型疫苗组和各空白对照组（p〈0.05）。结论：HA纳米颗粒载体介导转染hGM-CSF基因能增加HepG2细胞疫苗的免疫原性,转hGM-CSF基因HepG2细胞疫苗可有效诱导PBMC增殖、分化,增加INF-γ的分泌,提高其对HepG2细胞的杀伤作用。     

蚕豆萎蔫病毒2中国分离物全基因组结构及可能的基因表达方式

报道了蚕豆萎蔫病毒2的B935分离物全基因组序列。RNA1和RNA2分别由5956和3601个核苷酸组成[不包括3‘端未知长度的poly（A）尾巴]。RNA1和RNA2均包含单个阅读框,分别编码分子量为210063（210kD）和119002（119kD）的蛋白质。对外壳蛋白N端氨基酸序列测定表明,外壳蛋白大、小亚基（LCP、SCP）为119kD蛋白质在466／467位的Q／C和868／869位的Q／A位点切割形成的中间和C端蛋白,而端蛋白与豇豆花叶病毒58kD/48kD移动蛋白具有一定的同源性,并且包含一个类似病毒移动蛋白特有的rNTP结合域,推断为移动蛋白。通过与豇豆花叶病毒科病毒RNA1编码的多聚蛋白的同源性比较及功能蛋白保守序列的查找,表明210kd蛋白质可切割形成RdRp、蛋白酶、包含NTP结合域蛋白（NTBM）、蛋白酶辅助因子和Vpg等成熟蛋白,并进一步对其切割位 作了分析,根据LCP和SCP氨基酸序列所作的系统关系树充分证明了蚕豆萎蔫病毒（BBWV）两个血清型,确应命名为两个不同的病毒。     

乳酸堆积和二氯乙酸钠对肝癌细胞凋亡及bax、bcl-2表达和caspase-3活性的影响

目的：探讨乳酸堆积和二氯乙酸钠（OCA）对肝癌细胞（HepG2）凋亡和bax、bcl-2表达及caspase-3活性的影响。方法：通过体外培养HepG2,建立稳定的体外培养模型,配制成终浓度分别为0mmol／L、1．0mmol／L、2．0mmol／L、4．0mmol／L、8．0mmol／L的乳酸培养液以及在不同浓度乳酸组中加入终浓度为10^-3mmol／LDCA培养液与HepG2共同培养,其中以0mmol／L乳酸组为对照组。采用MTT法检测乳酸对HepG2的抑制率,流式细胞仪检测乳酸和DCA对HepG2的凋亡百分率,用Real-time PCR法测定bax及bcl-2mRNA的表达,用免疫荧光法检测caspase-3的活性。结果：乳酸对HepG2的IC50值为13．6mol／L,与对照组比较,随着乳酸浓度的增加,HepG2凋亡率增加,baxmRNA表达升高,bcl-2mRNA的表达降低,caspase-3活性增加,其中1．0mmol／L乳酸组与对照组比较（P〉0．05）,2．0mmol／L,4．0mmol／L和8．0mmol／L乳酸组与对照组比较差异有统计学意义（P〈0．05）。加入DCA后．HepG2凋亡减少,2．0mmol／L乳酸＋DCA组、4．0mmol／L乳酸＋DCA组、8．0mmol／L乳酸＋DCA组与同浓度的乳酸组比较,baxmRNA表达减少（P〈0．05）,bcl-2mRNA表达增加（P〈0．05）,caspase-3活性减低（P〈0．05）。结论：乳酸可诱导HepG2凋亡,且随着乳酸浓度的增高,HepG2的凋亡率增加,其机制可能是通过对bcl-2及baxmRNA表达的改变以及激活caspase-3活性而实现,DCA可以降低HepG2凋亡,对乳酸堆积造成的HepG2凋亡有抑制作用。     

地塞米松对HepG2细胞分泌载脂蛋白的影响

以培养的人肝癌细胞系HepG2为研究对象,采用“冻干浓缩培养液载脂蛋白测定法”,考察了地塞米松对HepG2细胞载脂蛋白(apolipoprotein,apo)AⅠ、AⅡ、CⅢ、B100及E分泌的影响.结果表明：地塞米松对HepG2细胞apoAⅠ和apoE的分泌有促进作用,对apoAⅡ、apoB100和apoCⅢ的分泌有抑制作用,且这种作用随地塞米松浓度的增加而增强.当培养液中地塞米松的浓度为5.5×10^－5mol/L时,apoAⅠ和apoE的分泌分别增加36.6%和49.4%（P＜0.01）,apoAⅡ、apoB100和apoCⅢ的分泌分别减少38.9%、31.9%和29.8%（P＜0.01）.     

小麦低分子量麦谷蛋白亚基与面团流变学特性关系的研究

采用十二烷基硫酸钠-聚丙稀酰胺凝胶电泳(SDS-PAGE)分离方法,以牛血清蛋白(67kD)和卵清蛋白(43kD)为分子量标记,对甘肃河西灌区近几年选育的17个小麦品系以及大面积栽培的2个春小麦品种的低分子量麦谷蛋白亚基组成以及不同亚基对面团流变学特性(面团韧性P、延伸性L、面团筋力W)的影响进行分析。19个试验材料中共标记出从35．2～60．5kD的LMW-GS共32条谱带;通过单因素方差分析(ANOVA)和逐步回归分析确定出对面团流变学特性P、L、W值影响显著的7个LMW-GS,分子量由高到低为：52．7kD、52kD、49．3kD、46．7kD、44．8kD、44．2kD、35．2kD。其中35．2kD和46．7kD亚基能显著地增加面团P值,44．8kD亚基能显著地降低面团P值;44．2kD和49．3kD亚基显著增加面团L值,52．7kD亚基降低面团L值;44．8kD、52．7kD亚基能显著降低面团的W值,52．0kD和46．7kD亚基能显著提高面团W值。     

施氏鲟卵黄蛋白原及其相关蛋白的研究

采用凝胶柱层析、聚丙烯凝胶电泳、免疫印迹（Western blotting）和免疫扩散等方法对施氏鲟卵黄蛋白原（Vi-tellogenin,Vg）及其相关蛋白（Yolk protein,YP）进行了研究。结果表明,施氏鲟血清Vg是一种糖脂磷蛋白,其相对分子量为410kD,由分子量为205kD的两个同源亚基组成。Vg的3种相关蛋白YP1、YP2和YP3。其中YP1相对分子量为370kD,是一种糖脂磷蛋白,由相对分子量为97kD和33kD的两个亚基构成。YP2是一种相对分子量为144kD的磷脂蛋白,由相对分子量为94kD和45kD的2个亚基构成。YP3为相对分子量为66kD的磷蛋白,由相对分子量为30kD的同源亚基构成。     

SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis

Rationale: Glioma is the most common primary malignant tumor of human central nervous system, and its rich vascular characteristics make anti-angiogenic therapy become a therapeutic hotspot. However, the existence of glioma VM makes the anti-angiogenic therapy ineffective. SUMOylation is a post-translational modification that affects cell tumorigenicity by regulating the expression and activity of substrate proteins.Methods: The binding and modification of IGF2BP2 and SUMO1 were identified using Ni²⁺-NTA agarose bead pull-down assays, CO-IP and western blot; and in vitro SUMOylation assays combined with immunoprecipitation and immunofluorescence staining were performed to explore the detail affects and regulations of the SUMOylation on IGF2BP2. RT-PCR and western blot were used to detect the expression levels of IGF2BP2, OIP5-AS1, and miR-495-3p in glioma tissues and cell lines. CCK-8 assays, cell transwell assays, and three-dimensional cell culture methods were used for evaluating the function of IGF2BP2, OIP5-AS1, miR-495-3p, HIF1A and MMP14 in biological behaviors of glioma cells. Meantime, RIP and luciferase reporter assays were used for inquiring into the interactions among IGF2BP2, OIP5-AS1, miR-495-3p, HIF1A and MMP14. Eventually, the tumor xenografts in nude mice further as certained the effects of IGF2BP2 SUMOylation on glioma cells.Results: This study proved that IGF2BP2 mainly binds to SUMO1 and was SUMOylated at the lysine residues K497, K505 and K509 sites, which can be reduced by SENP1. SUMOylation increased IGF2BP2 protein expression and blocked its degradation through ubiquitin-proteasome pathway, thereby increasing its stability. The expressions of IGF2BP2 and OIP5-AS1 were up-regulated and the expression of miR-495-3p was down-regulated in both glioma tissues and cells. IGF2BP2 enhances the stability of OIP5-AS1, thereby increasing the binding of OIP5-AS1 to miR-495-3p, weakening the binding of miR-495-3p to the 3''UTR of HIF1A and MMP14 mRNA, and ultimately promoting the formation of VM in glioma.Conclusions: This study first revealed that SUMOylation of IGF2BP2 regulated OIP5-AS1/miR-495-3p axis to promote VM formation in glioma cells and xenografts growth in nude mice, providing a new idea for molecular targeted therapy of glioma.     

IGF2BP2, an RNA-binding protein regulates cell proliferation and osteogenic differentiation by stabilizing SRF mRNA

Osteoblast proliferation and osteogenic differentiation (OGD) are regulated by complex mechanisms. The roles in cell proliferation and OGD of RNA-binding proteins in the insulin-like growth factor 2 mRNA-binding protein (IGF2BP) family remain unclear. To elucidate this, we examined the differential expression of IGF2BP2 in OGD and osteoporosis, and the expression profile of IGF2BP2-binding RNA in vitro. We screened the GEO database for differential expression of IGF2BP in OGD and osteoporosis, and verified the RNAs interacting with IGF2BP2 via RNA immunoprecipitation sequencing assays. The proliferation and OGD of IGF2BP2- and serum response factor (SRF)-treated cells, and their regulatory mechanisms, were examined. IGF2BP2 was differentially expressed in OGD and osteoporosis. The RNA immunoprecipitation sequencing assay identified all of the RNAs that bind with IGF2BP2, and revealed SRF as a target of IGF2BP2. IGF2BP2 and SRF inhibition impaired MC3T3-E1 cell growth but promoted OGD. The mRNA stability analysis revealed that IGF2BP2 enhanced SRF mRNA stability against degradation. In summary, IGF2BP2 is a potential biomarker and therapeutic target for osteoporosis and OGD.     

Identification of a type 1 insulin-like growth factor binding protein (IGF BP) in serum from rats with diabetes mellitus

Circulating insulin-like growth factor binding protein (IGF BP) activity is increased in animals with streptozotocin-induced diabetes. Separation of BPs by SDS/PAGE for ligand and immunoblot analysis revealed that a 32,000 molecular weight BP is present and increased in diabetic serum. This BP is immunologically distinct from the low molecular weight fetal rat BP (rBP2) and is related to the human amniotic fluid BP (hBP1) that is increased in patients with insulin dependent diabetes mellitus.     

肾综合征出血热纯化疫苗的SDS-PAGE分析

为了证明蛑综合征出血热纯化疫苗的主要成分坦病毒蛋白,采用出血热纯化疫苗经浓缩后进行SDS－PAGE和Western-blotting分析。结果 经SDS－PAGE显示,肾综合征出血热纯化疫苗有三条蛋白带,分子量分别约为70kD、55kD和50kD,与汉坦病毒三种结构蛋白（糖蛋白G1、G2和核蛋白NP）的分子量相符;经Western-blotting显示,分子量50kD的蛋白带反应阳性,分子量70kD和55kD的蛋白带无反应,认定出血热纯化疫苗的主要成分为汉坦病毒蛋白,主要由G1、G2和NP三种结构蛋白构成。     

Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs

The RNA-binding protein IGF2BP1 (IGF-II mRNA binding protein 1) stabilizes the c-myc RNA by associating with the Coding Region instability Determinant (CRD). If and how other proteins cooperate with IGF2BP1 in promoting stabilization of the c-myc mRNA via the CRD remained elusive. Here, we identify various RNA-binding proteins that associate with IGF2BP1 in an RNA-dependent fashion. Four of these proteins (HNRNPU, SYNCRIP, YBX1, and DHX9) were essential to ensure stabilization of the c-myc mRNA via the CRD. These factors associate with IGF2BP1 in a CRD-dependent manner, co-distribute with IGF2BP1 in non-polysomal fractions comprising c-myc mRNA, and colocalize with IGF2BP1 in the cytoplasm. A selective shift of relative c-myc mRNA levels to the polysomal fraction is observed upon IGF2BP1 knockdown. These findings suggest that IGF2BP1 in complex with at least four proteins promotes CRD-mediated mRNA stabilization. Complex formation at the CRD presumably limits the transfer of c-myc mRNA to the polysomal fraction and subsequent translation-coupled decay.     

Secretion of noncomplexed 'Big' (10-18 kD) forms of insulin-like growth factor-II by 12 soft tissue sarcoma cell lines

The paraneoplastic production of pro-insulin-like growth factor-II (IGF-II) forms causes tumour hypoglycaemias and presumably also has an effect on tumour cell growth. We investigated the molecular weights of IGF-II forms and their ability to form complexes with IGF binding proteins (IGFBPs) in conditioned culture media (CM) from 12 paediatric soft tissue sarcoma (STS) cell lines and from two healthy fibroblast lines. Untreated CM were separated by size exclusion chromatography using biocompatible HPLC. Subsequently, IGF-II, IGFBP-2 and IGFBP-3 were determined in the HPLC fractions by specific RIAs. In the CM, IGF-II concentrations between 0.5 and 8.6 ng/10(6) cells were measured but no IGF-I was detectable. Parallel to this investigation, a high IGF-II mRNA level averaging 44.4 +/- 29.7% was measured by semi-quantitative RT-PCR. The STS cell lines secreted a higher proportion of big-IGF-II forms reaching 10-18 kD (10-33% of the total IGF-II secreted) compared to the healthy fibroblasts (2.5-5%). At the same time, the proportion of IGF-II bound with IGFBP in complexes of 35- 70 kD and 150 kD was reduced by up to 85% in CM from tumour cells. The tumour cell lines apparently secrete a different spectrum of IGF-II forms than healthy fibroblasts. The reduced ability to form complexes with IGFBP and the higher molecular weight of the IGF-II forms produced by the tumour cells indicate that these forms could in fact be the known tumour-associated pro-IGF-II forms. Due to these characteristics, the big-IGF-II forms probably have an altered biological effect on the tumour cells when compared to IGF-II.     

IGF2BP1

The oncofetal RNA-binding protein IGF2BP1 (IGF2 mRNA binding protein 1) controls the cytoplasmic fate of specific target mRNAs including ACTB and CD44. During neural development, IGF2BPs promote neurite protrusion and the migration of neuronal crest cells. In tumor-derived cells, IGF2BP1 enhances the formation of lamellipodia and invadopodia. Accordingly, the de novo synthesis of IGF2BP1 observed in primary malignancies was reported to correlate with increased metastasis and an overall poor prognosis. However, if and how the protein enhances metastasis remains controversial. In recent studies, we reveal that IGF2BP1 promotes the directed migration of tumor-derived cells in vitro by controlling the expression of MAPK4 and PTEN. The IGF2BP1-facilitated inhibition of MAPK4 mRNA translation interferes with MK5-directed phosphorylation of the heat shock protein 27 (HSP27). This limits G-actin sequestering by phosphorylated HSP27, enhances cell adhesion and elevates the velocity of tumor cell migration. Concomitantly, IGF2BP1 promotes the expression of PTEN by interfering with PTEN mRNA turnover. This results in a shift of cellular PtdIns(3,4,5)P₃/PtdIns(4,5)P₂ ratios and enhances RAC1-dependent cell polarization which finally promotes the directionality of tumor cell migration. These findings identify IGF2BP1 as a potent oncogenic factor that regulates the adhesion, migration and invasiveness of tumor cells by modulating intracellular signaling.     

Klebsiella pneumoniae secreted protein-containing antigens in the system of adaptive immunity

The study was aimed at the evaluation of the antigenic properties of K. pneumoniae secreted protein-containing antigens with a molecular weightt of 21 and 34-35 kD, obtained from supernatant culture fluid. As confirmed by the method of flow cytofluorimetry, the protein-containing fractions belonged to the secreted components of the microbial cell. The fraction with a molecular weight of 34-35 kD possessed high antigenic activity and contributed to the formation of specific antibodies after the immunization of mice. At the same time none of the protein fractions lead to an increase in the level of autoantibodies in mouse blood sera to organ-unspecific and organ-specific antigens. As revealed by the method of solid-phase, in 6 (27.3%) from 22 patients of patients with rhizomelic spondylitis had an increased level of IgG to K. pneumoniae cell-wall antigens with a molecular weight of 34-35 kD. An increase in the level of IgG to the secreted protein-containing fraction with a molecular weight of 34-35 kD was detected only in one patient (4.5%) (p<0.05).     

IGF2BP1: A post-transcriptional “driver” of tumor cell migration

The oncofetal RNA-binding protein IGF2BP1 (IGF2 mRNA binding protein 1) controls the cytoplasmic fate of specific target mRNAs including ACTB and CD44. During neural development, IGF2BPs promote neurite protrusion and the migration of neuronal crest cells. In tumor-derived cells, IGF2BP1 enhances the formation of lamellipodia and invadopodia. Accordingly, the de novo synthesis of IGF2BP1 observed in primary malignancies was reported to correlate with increased metastasis and an overall poor prognosis. However, if and how the protein enhances metastasis remains controversial. In recent studies, we reveal that IGF2BP1 promotes the directed migration of tumor-derived cells in vitro by controlling the expression of MAPK4 and PTEN. The IGF2BP1-facilitated inhibition of MAPK4 mRNA translation interferes with MK5-directed phosphorylation of the heat shock protein 27 (HSP27). This limits G-actin sequestering by phosphorylated HSP27, enhances cell adhesion and elevates the velocity of tumor cell migration. Concomitantly, IGF2BP1 promotes the expression of PTEN by interfering with PTEN mRNA turnover. This results in a shift of cellular PtdIns(3,4,5)P₃/PtdIns(4,5)P₂ ratios and enhances RAC1-dependent cell polarization which finally promotes the directionality of tumor cell migration. These findings identify IGF2BP1 as a potent oncogenic factor that regulates the adhesion, migration and invasiveness of tumor cells by modulating intracellular signaling.